BioMarin Pharmaceuticals
BMRN
BMRN
538 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 191 increasing their positions, 192 reducing their positions, and 70 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
538
Holders Change
-18
Holders Change %
-3.24%
% of All Funds
9.1%
Holding in Top 10
12
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+100%
% of All Funds
0.2%
New
65
Increased
191
Reduced
192
Closed
70
Calls
$85.1M
Puts
$94.2M
Net Calls
-$9.1M
Net Calls Change
-$54.5M
Top Buyers
| 1 |
Barclays
London,
United Kingdom
|
+$166M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$108M |
| 3 |
SIG
Senator Investment Group
New York
|
+$70.4M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$58.1M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$54.2M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$369M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$88.2M |
| 3 |
ClearBridge Investments
New York
|
-$81.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$77.7M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
-$62.9M |
